KPN and iBASIS Renew International Services Outsourcing Deal
iBASIS, the leading provider of communications solutions for operators and digital players worldwide, and KPN, the Netherlands’ leading telecom company, announced today that they have renewed their outsourcing agreement for Voice and Mobile services for three years.
Since its sale by KPN in 2019, iBASIS and its global team have been dedicated to bringing KPN best-in-class services, leveraging the group consolidation and economy of scale strategy of its owner, Tofane Global. Cost stability, capacity planning, and fraud prevention have been instrumental in sustaining the Dutch operator’s traffic growth.
The renewal underscores the success of iBASIS’ model and long-term relationship with managing KPN’s international traffic growth, including IPX cooperation to handle the surge in mobile data traffic. iBASIS reports an 80% year-on-year growth in Diameter traffic, which has enabled KPN to deliver reliable, high-speed data roaming services to its subscribers. The network scalability has been critical in meeting the explosive 4G and 5G mobile data roaming demand, including traffic peaks resulting from the rise of M2M connections.
“iBASIS has been a trusted partner of KPN for the past six years, managing our international voice and mobile services. Leveraging their consolidation model and economies of scale, we outsource nearly 100% of our voice business to iBASIS. Their partner program is focused on delivering quality, transparency, and actionable business insights,” said Michel van Wissen, Executive Vice President, Wholesale, KPN. “We have extended our partnership for another three years. Our excitement is based on proven past successes and on the innovation iBASIS continues to demonstrate in meeting the challenges providers face now and in the future.”
Outsourcing international voice and mobile services also enables KPN to focus on its retail and wholesale business as well as technology initiatives associated with developing these segments.
“We enjoy a strong and mutually beneficial relationship with KPN on voice and mobile services,” added Edwin van Ierland, CEO, iBASIS Voice & Mobile Data. “We are more than a supplier; we are a growth partner. As such, we are very motivated to help KPN leverage our global platform and capabilities to the fullest. The renewal illustrates our excellent relationship, centered on transparency and open communication. It again demonstrates that the outsourcing model chosen by KPN is highly effective.”
“KPN’s three-year renewal is the recognition of iBASIS/Tofane past and future excellence thanks to our unique mix of scale, innovation, and entrepreneurship,” said Alexandre Pébereau, Group CEO and Founder, Tofane Global. “Our performance is recognized again by ROCCO as a top Tier One International Voice Carrier,* Telegeography Fourth Voice Carrier,** and First Independent Carrier.”
In 2023, iBASIS was ranked by 227 MNOs as the top Tier One International Voice Carrier for Performance, Performance+, Leadership, General Rating, and Overall Rating, with the highest results for Global Presence, Local Expertise, R&D Investment, Trusted, Innovative, Dynamic, and Enabler.*
*ROCCO Research: International Voice Carrier Market Impact Report 2023
**Telegeography International Voice Report 2024
About iBASIS
iBASIS is the leading communications solutions provider enabling operators and digital players worldwide to perform and transform. Powered by Tofane Global, iBASIS is the first independent communications specialist and Tier One IPX vendor with 800+ LTE destinations. iBASIS today serves 1,000+ customers across 28 locations worldwide. iBASIS optimizes global connectivity, quality, and security so customers achieve high return on voice, SMS A2P messaging, mobile data, 5G roaming, and IoT.
About KPN
KPN has been the leading provider of telecommunications and IT services in the Netherlands for almost 140 years. Everyone in the Netherlands uses the KPN network on a daily basis, either directly or indirectly, from the high-speed fibre networks in the ground to payment card machines in shops, or the matrix boards above the motorways. Via the network of the Netherlands, in which KPN continuously invests by rolling out fibre and the introduction of new technologies such as the 5G mobile network, KPN serves consumers and business customers with services for telephony, data, television, internet-of-things, cloud, workplaces and security. KPN has an open network on which other providers also offer services. More information is available at www.kpn.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240220905856/en/
Contact information
iBASIS Media Contact
Jason McGee-Abe
26FIVE Global Lab
iBASIS@26FIVE.com
+ 44 7970 237682
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Axelspace: Notice of Signing a Service contract for In-Orbit Demonstration with Pale Blue, Inc.22.12.2025 10:00:00 CET | Press Release
Axelspace Corporation (“Axelspace”), a leading microsatellite company committed to making “Space within Your Reach,” has entered into a service agreement with Pale Blue Inc. (“Pale Blue”), a company that develops, manufactures, and sells thrusters (engines) for small satellites, for an in-orbit demonstration, as detailed below. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251219321165/en/ Jun Asakawa, Co-founder & CEO of Pale Blue (left in photo) and Yuya Nakamura, President and CEO of Axelspace Axelspace provides AxelLiner Laboratory (AL Lab), a new service originating from the AxelLiner business that is specialized in in-orbit demonstration of space components. Under this contract, an in-orbit demonstration of a fast-start Hall thruster developed by Pale Blue is scheduled to be conducted in 2027. Nonetheless, conducting in-orbit demonstrations in a short period of time is known to be a significant challenge due to the in
Axelspace Signing Agreement on a Multi-Launch Arrangement and the Launch of New Satellites with Exolaunch22.12.2025 10:00:00 CET | Press Release
Axelspace Corporation (“Axelspace”), a leading microsatellite company committed to making “Space within Your Reach,” is pleased to announce a multi-launch agreement (MLA) with Exolaunch, a global launch integrator and leader in launch mission management, satellite integration and satellite deployment technologies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251219038364/en/ The Multi-Launch Agreement will accelerate the growth of Axelspace. In particular, one satellite scheduled for launch under the new Agreement will be used in the AxelLiner business’s in-orbit demonstration service, “AxelLiner Laboratory”. Exolaunch has already secured launches for eight (8) Axelspace’s satellites on the upcoming missions. Axelspace provides AxelLiner Laboratory (AL Lab), a new service originating from the AxelLiner business that is specialized in in-orbit demonstration of space components. Nonetheless, conducting in-orbit demonstration
Zambon Biotech Announces First Patient Dosed in Phase 3b ADIP Clinical Study of IPX203 in Parkinson’s Disease22.12.2025 10:00:00 CET | Press Release
Zambon Biotech, a specialized biotech company part of the Zambon group that aims to build a scientifically robust and commercially viable portfolio of innovative patient-oriented drugs through the scouting, acquisition, licensing and development of new molecules, today announced that the first participant with advanced Parkinson’s disease has been enrolled in the European Phase 3b ADIP (IPX203 in Advanced Parkinson’s disease) study, which is planned to evaluate the efficacy and safety of IPX203 versus immediate-release (IR) levodopa/carbidopa (LD/CD) in a regimen which has not yet been the focus of a Phase 3 trial. IPX203 is a novel, oral modified-release formulation of LD/CD designed for the treatment of Parkinson’s disease, the fastest growing neurological condition in the world according to the World Health Organization1. IPX203 contains immediate-release granules and extended-release beads, providing both a rapid onset of action and a longer duration of benefit, sustaining the levo
Pimicotinib Approved as Systemic Treatment in China for Tenosynovial Giant Cell Tumor22.12.2025 09:00:00 CET | Press Release
Merck, a leading science and technology company, announced today that following Priority Review, the China National Medical Products Administration (NMPA) has approved pimicotinib for the treatment of adult patients with symptomatic tenosynovial giant cell tumor (TGCT) for which surgical resection will potentially cause functional limitation or relatively severe morbidity. Pimicotinib, a colony stimulating factor-1 receptor (CSF-1R) inhibitor developed by Abbisko Therapeutics Co., Ltd., Shanghai, China, is the first Chemical Drug Class 1 approved in China for the treatment of TGCT. “We are continuing to deliver on our commitment to improving the lives of patients with rare tumors with this first-in-the-world regulatory approval of pimicotinib,” said Danny Bar-Zohar, CEO Healthcare and Member of the Executive Board of Merck. “This approval is a significant step forward in further strengthening our leadership in rare tumors, while offering patients the opportunity to change the course of
Incyte Japan Announces Approval of Minjuvi ® (tafasitamab) in Combination with Rituximab and Lenalidomide for the Treatment of Relapsed or Refractory Follicular Lymphoma22.12.2025 08:44:00 CET | Press Release
Incyte Biosciences Japan G.K. today announced approval from Japan's Ministry of Health, Labour and Welfare (MHLW) for Minjuvi® (tafasitamab) in combination with rituximab and lenalidomide for adult patients with relapsed or refractory follicular lymphoma (2L+ FL). “Today's approval of Minjuvi in combination with rituximab and lenalidomide marks a significant milestone as the first dual-targeted CD19 and CD20 immunotherapy combination for relapsed or refractory FL in Japan,” said Yasuyuki Ishida, General Manager, Incyte Biosciences Japan. “By improving progression-free survival, Minjuvi offers a chemotherapy-free option for eligible patients with relapsed or refractory disease. This approval underscores our commitment to bridging critical treatment gaps to patients and families affected by this challenging disease in Japan.” The approval is based on the pivotal Phase 3 inMIND trial, which enrolled 654 adult patients, including patients based in Japan. The study demonstrated that Minjuvi
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom